as 02-14-2025 9:51am EST
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Founded: | 1940 | Country: | Spain |
Employees: | N/A | City: | N/A |
Market Cap: | 5.5B | IPO Year: | 2006 |
Target Price: | N/A | AVG Volume (30 days): | 856.8K |
Analyst Decision: | Strong Sell | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.27 | EPS Growth: | N/A |
52 Week Low/High: | $5.30 - $9.96 | Next Earning Date: | 01-01-0001 |
Revenue: | $7,814,096,584 | Revenue Growth: | 7.21% |
Revenue Growth (this year): | 9.53% | Revenue Growth (next year): | 8.09% |
GRFS Breaking Stock News: Dive into GRFS Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Bloomberg
23 days ago
MT Newswires
a month ago
GlobeNewswire
a month ago
Reuters
a month ago
Simply Wall St.
a month ago
Bloomberg
2 months ago
Bloomberg
2 months ago
The information presented on this page, "GRFS Grifols S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.